CLYM
Climb Bio Inc4.6200
+0.8100+21.3%
Dec 16, 4:00:01 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
315.01MP/E (TTM)
-Basic EPS (TTM)
-0.59Dividend Yield
0%Recent Filings
10-K
FY2025 results
Climb Bio posted a FY2025 net loss of $59.9M, up from $73.9M in FY2024, driven by ramped R&D to $46.7M from $14.3M as budoprutug Phase 2 in pMN hit FPI in November and CLYM116 Phase 1 launched in December—yet cash burn moderated with $160.7M runway into 2028. Q4 spend accelerated on trial momentum, with budoprutug enrolling across pMN/ITP/SLE and SC formulation data pending H1 2026; no revenue, but $8.3M interest income cushioned the hit. Liquidity solid at $160.7M post-RA Capital warrant exchange, no debt. Clinical delays from trial enrollment or regulatory holds could stall momentum.
8-K
Q4 results, cash into 2028
Climb Bio reported Q4 and full-year 2025 results, with cash at $160.7 million funding operations into 2028, yet R&D expenses jumped to $46.7 million from $14.3 million amid pipeline acceleration. Dosing wrapped in budoprutug's subcutaneous Phase 1 trial; data due H1 2026 alongside H2 readouts from pMN, ITP, and SLE studies. Pipeline advances briskly. CLYM116 Phase 1 enrollment continues, initial data mid-2026.
8-K
Pipeline progress, data catalysts ahead
Climb Bio announced pipeline advances on January 8, 2026: first patients dosed in budoprutug's PrisMN Phase 2 for pMN in November 2025, China IND clearance for SLE Phase 1b in December 2025, and first cohorts dosed in subcutaneous budoprutug and CLYM116 Phase 1 trials. Data readouts loom across programs in H1-H2 2026. Cash funds operations into 2028. Timelines hinge on trial execution.
8-K
Climb sues over $3M milestone
Climb Bio filed a Delaware Superior Court complaint on December 31, 2025, against Alumis and subsidiary Acelyrin, seeking declaratory judgment that its budoprutug candidate isn't a 'Product' under their January 11, 2024 Asset Purchase Agreement—due to no Royalty-Bearing Patents transferred or filed. Alumis demands a $3 million Phase 2 milestone payment by January 1, 2026, after Climb dosed its first patient on November 17, 2025. No patents, no payout.
8-K
RA Capital share-for-warrant exchange
Climb Bio exchanged 20,440,000 common shares held by RA Capital affiliate for an equal number of pre-funded warrants at $0.0001 exercise price on December 11, 2025. Post-exchange, 47.7 million shares outstanding; RA Capital retains 23% voting power. RA agrees to vote excess holdings proportionally. Ownership capped at 33%.